Senti Biosciences Inc. (SNTI)
NASDAQ (CM) NASDAQ (CM) Primary Summary
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences Inc.
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into Senti Biosciences Inc.
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
Senti Biosciences Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| GL Geulah Livshits Chardan Capital | 27,628.44 | $22,325.41 | $27,628.44 | $5,303.03 | 23.75% |
Senti Biosciences Inc. (SNTI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Senti Biosciences Inc. ever had a stock split?
Senti Biosciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Timothy K. Lu CEO | NASDAQ (CM) Exchange | 816944102 CUSIP |
| US Country | 34 Employees | - Last Dividend | 18 Jul 2024 Last Split | - IPO Date |
Overview
Senti Biosciences, Inc. stands at the forefront of preclinical biotechnology innovation, differentiating itself by its dedicated focus on engineering next-generation cell and gene therapies. These therapies are developed through the company's proprietary gene circuit platform technologies aimed at treating a wide array of diseases. With its inception in 2016 and headquartered in South San Francisco, California, Senti Biosciences drives into the future with a mission to leverage cutting-edge biotechnological approaches for medical advancements. The company’s strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd, specifically for the clinical development of one of its leading product candidates, SENTI-301A for solid tumors, highlights its commitment to global partnerships that foster significant therapeutic breakthroughs.
Products and Services
- SENTI-202
- SENTI-301A
- SENTI-401
- Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform
This innovative product stands as a leading figure in Senti Biosciences' repertoire, designed as a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy. The primary aim is to precisely target and annihilate cancer cells while crucially sparing healthy bone marrow cells. SENTI-202 showcases the company's focus on creating solutions that are not only effective in addressing targeted cancer cells but also in minimizing collateral damage to the patient's overall health.
Targeted at hepatocellular carcinoma, SENTI-301A reflects Senti Biosciences’ dedication to addressing some of the most challenging cancers. This product emphasizes the company's strategic direction towards solid tumors, leveraging its gene circuit technologies to introduce groundbreaking treatments capable of providing new hope for patients suffering from this severe form of liver cancer.
With a specific focus on colorectal cancer (CRC), SENTI-401 represents a Logic Gated off-the-shelf CAR-NK cell therapy engineered to seek out and destroy CRC cells. The attention to colorectal cancer underscores the company’s commitment to tackling prevalent yet challenging cancers, often requiring novel treatment strategies for effective management and potentially better outcomes.
This platform underpins Senti Biosciences’ approach to identifying and validating NOT GATE antigen candidates alongside the discovery of tumor-associated antigens present in cancer cells. It’s a testament to the company’s investment in foundational research and development, aiming to provide more targeted and efficient therapies by understanding the very markers that define different cancer cells.
